https://www.selleckchem.com/pr....oducts/Furosemide(La
018), as well as worse overall survival (HR = 2.00; 95% CI 1.21 - 3.32; p = 0.007) and progression-free survival (HR = 2.34; 95% CI 1.50 - 3.67; p less then 0.001).There was no difference in distant recurrence (HR = 1.19; 95% CI 0.57 - 2.52; p = 0.64). CONCLUSIONS We found superior outcomes in patients with early-stage NSCLC treated with lobectomy compared to SBRT, including locoregional control. These findings should be interpreted with caution, due to selection bias, but underscore the importance of robust randomized prospec
Like
Comment
Share
